{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Tornyos D"],"pubmed_abstract":["Gliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represent alone or in combination a promising treatment option for patients with type II diabetes mellitus. In addition to glucose control, these drugs provide benefits including reduced risk of long-term cardiovascular (CV) and renal complications. Several trials evaluated gliflozins in patients with various degrees of cardiac dysfunction with heterogeneous results. We aimed to perform a comprehensive analysis of the effect of gliflozins on CV outcomes. Systematic searches of electronic databases were conducted until September 2022. Multiple treatment network meta-analysis was performed in R. Random-effects model was used to combine risk estimates across trials calculating risk ratio (RR) with 95% confidenc"],"journal":["Frontiers in cardiovascular medicine"],"pagination":["1041200"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9760750"],"repository":["biostudies-literature"],"pubmed_title":["Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials."],"pmcid":["PMC9760750"],"pubmed_authors":["Faludi R","Tornyos D","El Alaoui El Abdallaoui O","Kupo P","Komocsi A","Meuer M","Lukacs R"],"additional_accession":[]},"is_claimable":false,"name":"Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials.","description":"Gliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represent alone or in combination a promising treatment option for patients with type II diabetes mellitus. In addition to glucose control, these drugs provide benefits including reduced risk of long-term cardiovascular (CV) and renal complications. Several trials evaluated gliflozins in patients with various degrees of cardiac dysfunction with heterogeneous results. We aimed to perform a comprehensive analysis of the effect of gliflozins on CV outcomes. Systematic searches of electronic databases were conducted until September 2022. Multiple treatment network meta-analysis was performed in R. Random-effects model was used to combine risk estimates across trials calculating risk ratio (RR) with 95% confidenc","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-26T09:47:08.88Z","creation":"2025-04-06T13:09:56.759Z"},"accession":"S-EPMC9760750","cross_references":{"pubmed":["36545024"],"doi":["10.3389/fcvm.2022.1041200"]}}